HMGCR
3-hydroxy-3-methylglutaryl-coenzyme A reductase
As of the edition of 20 October 2026, HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase, UniProt P04035) has 10 drugs tested at it and 26 companies on the list, 1 on route A and 10 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P04035
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 24
- Disease areas
- Nutrition and metabolism; Heart and blood vessels; Cancer; Nervous system; Hormones; Urinary and reproductive; Immune system; Skin and connective tissue
- Registered trials of its drugs
- 1,728
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 7 |
| Went quiet | 1 |
| Stopped | 1 |
| Withdrawn from market | 1 |
| Total | 10 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Atorvastatin | Marketed | Phase 4 | none listed |
| Rosuvastatin | Marketed | Phase 4 | none listed |
| Simvastatin | Marketed | Phase 4 | none listed |
| Pravastatin | Marketed | Phase 4 | none listed |
| Pitavastatin | Marketed | Phase 4 | none listed |
| Lovastatin | Marketed | Phase 4 | none listed |
| Fluvastatin | Marketed | Phase 4 | none listed |
| Apomine | Stopped | Phase 2 | none listed |
| Bemfivastatin | Went quiet | Phase 2 | none listed |
| Cerivastatin | Withdrawn from market | No phase stated | none listed |
10 of 10 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 10 |
| Engaged | 10 |
| Undetermined | 5 |
| Total on the list | 26 |
| Company | Route |
|---|---|
| Novartis | Route B |
| Pfizer | Route B |
| Bristol Myers Squibb | Route B |
The other 23 companies at HMGCR
In the product26 companies in all; 23 are not named here, and no score is.
See the 26 companies at HMGCR, ranked, with the facts behind eachRequest access. Nothing is shown until you do.